“Rollins is many things,” says the Washington Post, “diatribist, confessor, provocateur, humorist, even motivational speaker…his is an enthusiastic and engaging chatter.” Rollins has toured the world as a spoken word artist, as frontman for both Rollins Band and Black Flag and as a solitary traveler with insatiable curiosity, favoring road-less-traveled locales in places such as Nepal, Sri Lanka, Siberia, North Korea, South Sudan and Iran.
10:45 ONE YEAR OF MEDICAL CANNABIS IN GERMANY – WHO BENEFITS?
One year ago, Germany radically changed its medical cannabis laws. Since then, the number of German medical cannabis patients and their demand for medicine has been growing fast, creating a rapidly changing landscape concerning patients, doctors, pharmacies, health insurers, importers and would-be domestic producers. Georg Wurth, head of the German Hemp Association (DHV), will provide a policy overview concerning all key aspects of the industry and delve into their respective nuances.
Since the first Canadian producers were able to export medical cannabis to Germany in 2016, numerous companies have received import and export licenses for the largest EU market. Meanwhile six producers, most of them from Canada, are offering more than thirty medicinal cannabis strains and extracts to German patients. At the same time, the number of patients is rising exponentially.
German medical cannabis is sold exclusively through pharmacies. Germany’s pharmacies currently sell much more cannabis than originally expected, and many strains are sold out due to high demand. Some pharmacies already specialize in cannabis, offering patients the widest possible selection or preordering flower, and/or extract, long in advance. Political parties in Germany have recently called for the participation of pharmacies in recreational cannabis pilot projects.
The recent developments in the German medical cannabis market are creating business opportunities not unlike what has happened in Canada and the U.S. Dr. Walter Späth will explain the legal framework of the German Medical Cannabis System and describe current business opportunities regarding Medical cannabis cultivation, cannabis import licenses, and the CBD market. In addition, Dr. Späth will give an outlook on how the cannabis market in Germany could develop in the future.
14:45 INVESTING IN CANNABIS/HEMP – THE ANCILLARY MARKET OPPORTUNITY
Ancillary businesses can be broadly defined as all those companies that provide the licensed business holders services to conduct day to day operations. Categories such as Data, Software, Technology (both electronic and scientific), HR/Payroll, Payment Solutions, Point of Sale, Tracking, Bottling, etc. Various markets in different parts of the world mature in unique ways. Each of these must be understood in order to recognize the opportunity in each market at its individual life in the cycle of growth that is the cannabis/hemp industry. We will discuss at macro level what this looks today and moving forward.
16:00 RISING FROM THE ASHES – LEARNINGS FROM THE PREMIUM CIGAR INDUSTRY
While cannabis and tobacco have vast differences (medicinal value, addiction rate, etc.), many parallels can be drawn between the saturated cigar industry and the burgeoning cannabis market. The stringent European Union market regulations in place for tobacco serve as a cautionary blueprint for what may be in store after Europe legalizes recreational cannabis. The cannabis industry must be concerned about the regulations of their home country, as well as the rules put in place by the EU and the 1961 UN Single Convention Treaty. Europe is seeing great progress on the medical front, and we can expect to see similar advances as more nations look to legalize for all adults in the near future, but regulatory hurdles could be extreme barriers from success. Benjamin Patock, with vast experience in the premium cigar industry, will share his experiences and provide his insight into the hurdles facing the cannabis industry and how businesses can succeed in overcoming those regulatory obstacles.
16:30 LIFETIME ACHIEVEMENT AWARD FOR DR. FRANJO GROTENHERMEN
It took patients 17 years to change the law in favor of medical cannabis. Dr. Franjo Grotenhermen is a MD and an internationally sought after cannabinoid-specialist, supporting Germany’s cannabis patients for over two decades.
10:15 HIGH STAKES – INTERNATIONAL CANNABIS INVESTMENTS AND OPPORTUNITIES
This session will present hard-hitting facts and advice for those considering investing or operating in the international cannabis markets. Investing in the “Green Rush” is extremely complex, and not for the faint of heart. Nic Easley, a globally recognized cannabis industry expert, multiple business owner, and venture fund manager will guide you through these emerging markets, helping you reduce risk while capturing upside opportunities to make impactful profitable companies. You’ll be better prepared to navigate these treacherous cannabis markets after attending this session.
Canada has clearly been an international leader on regulating cannabis commerce, and the nation is poised to capture an even bigger leadership role this year as the current government finalizes plans to fully legalize cannabis for all adults across the nation. Our panel of experts will discuss their experience in the industry since the start of Canadian cannabis commerce 5 years ago, focusing on lessons learned and providing tips on how businesses and entrepreneurs can avoid pitfalls and succeed in the burgeoning industry as it expands. These business experts will review the current international import/export situation and also discuss the plusses and minuses of taking your cannabis company public.
CBD is not subject to the Narcotics Act in most European countries. This has led to a true run on CBD products in the course of the public discussion on medical cannabis. The medical potential, its legal status and recent studies on anti-psychotic and anti-inflammatory properties of the non-psychoactive cannabinoid have caused a plethora of CBD products not only in Switzerland, Austria and Germany but also worldwide. In 2016, the first CBD-rich hemp flowers received approval as a tobacco substitute in Switzerland.
California, the sixth-largest economy in the world (and growing), is the most lucrative marijuana market in the world. Of course, cannabis commerce needs cultivators to succeed and such a huge market presents big opportunities for growers. Paul King will cover the ins and outs of commercially cultivating cannabis in the Golden State, providing first-hand experience, sharing some real-world anecdotes and even busting a few myths in the process. Paul will break down the numbers, methods and differences between different types of grows and will give insight into getting the proper types of investors and investment deals for your operation.
How is cybercurrency related to the cannabis industry? It is being discussed as a way to raise money for cannabis businesses and to create an end run on banking restrictions on the industry. There is a new disruptive technology called blockchain which supports cyber coins and digital tokens. The purpose of this talk is an engaging non-technical “blockchain for dummies” overview. It has been created for the purposes of introducing the topic of blockchain to cannabis company industry executives and fund managers, mid level managers, journalists, lawyers, media and marketing gurus and government agency regulators with a cannabis flair that will be fun, entertaining and most of all informative.
Deconstructing cannabis into its functional elements, understanding those components and their interactions, and reconstructing them into effective products are the focus of this talk. The ultimate challenge for 21st century cannabis industries is to create a variety of safe, individualized cannabis-based products and medications.
15:15 CANADIAN PHYSICIANS’ EXPERIENCE WITH MEDICAL CANNABIS
Our roundtable discussion with Canadian physicians currently prescribing cannabis to patients will delve into the multitude of issues facing patients and their doctors. Topics to be covered: How has the acceptance of medical cannabis by physicians and Canadian regulatory bodies changed over the years? Do patients have reasonable access to medicine or is the system broken? What benefits have doctors seen firsthand and what is the status of clinical trials? Will insurance coverage of medicinal cannabis be a game changer? What types of technology is used to help patients access cannabis? And more!
Specialization is a major factor attracting capital and helping grow the Cannabis sector at hyper-speed. As businesses scale, focused models will be a necessity from both economic and regulatory perspectives, allowing companies to position and embed into the Industry value chain alongside other ‘specialists’. Our panel of Industry experts will discuss strategy in identifying synergies in prospective strategic partners and offer their insights related to making these significant decisions which can be a determining factor in the survival and ultimate success of your business.
With ever-tightening regulations and oversight related to Cultivation, our panel of elite Industry scientists and growers will discuss topics ranging from regenerative farming and breeding, to organic pesticides and microbial screening methods as they relate to more stringent and evolving testing requirements.